Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.Amrubicin acts by inhibiting topoisomerase II and has been compared in clinical trials with topotecan a Topoisomerase I inhibitor. It has also been studied for the treatment of bladder carcinoma and gastric cancer.
This page contains content from the copyrighted Wikipedia article "Amrubicin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
